This activity is part 1 in a 3-part webinar curriculum.
Program Description
Patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) experience significant disease- and treatment-related burdens, such as a higher risk of mortality and frequency of injections, that negatively impact their quality of life and contribute to adherence issues. Specialty pharmacists can assist patients in addressing these burdens through identification of appropriate management strategies and treatment advances for AMD and DME to ensure improved adherence. Pharmacists should be also aware of the differentiating factors that influence treatment decisions for a patient. This first webinar of the curriculum will highlight challenges patients with AMD and DME experience, as well as opportunities to improve the quality of patient care with new and emerging therapies.
Target audience: Specialty pharmacists
Type of activity: Application
Release date: August 10, 2023
Expiration date: August 10, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational, intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology and risk factors of age-related macular degeneration (AMD) and diabetic macular edema (DME)
- Determine the disease burden, including the challenges with AME and DME traditional treatment therapies and the opportunities for improvement in quality of patient care
- Identify new and emerging therapies that address the treatment challenges and gaps associated with AMD and DME
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
